Equities Analysts Offer Predictions for Amedisys Q3 Earnings

Key Points

• William Blair has raised its Q3 2025 earnings estimate for Amedisys from $1.05 to $1.11 per share, with a full-year earnings estimate of $4.40 per share.
• Shares of Amedisys opened at $98.69 with a market capitalization of $3.24 billion and a price-to-earnings ratio of 38.40, reflecting strong investor interest.
• Amedisys reported Q2 2025 earnings of $1.54 EPS, which exceeded the consensus estimate of $1.39, along with a revenue of $621.86 million.

Amedisys, Inc. (NASDAQ:AMED - Free Report) - Stock analysts at William Blair upped their Q3 2025 earnings per share (EPS) estimates for Amedisys in a research note issued on Tuesday, July 29th. William Blair analyst M. Larew now anticipates that the health services provider will post earnings per share of $1.11 for the quarter, up from their prior forecast of $1.05. The consensus estimate for Amedisys' current full-year earnings is $4.40 per share. William Blair also issued estimates for Amedisys' Q4 2025 earnings at $1.19 EPS, FY2025 earnings at $5.09 EPS, Q2 2026 earnings at $1.38 EPS, Q3 2026 earnings at $1.25 EPS, Q4 2026 earnings at $1.24 EPS and FY2026 earnings at $4.78 EPS.

Amedisys (NASDAQ:AMED - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The health services provider reported $1.54 earnings per share for the quarter, beating analysts' consensus estimates of $1.39 by $0.15. Amedisys had a return on equity of 12.91% and a net margin of 3.56%. The company had revenue of $621.86 million for the quarter, compared to analyst estimates of $614.61 million. During the same quarter in the previous year, the company earned $0.98 EPS. The firm's revenue for the quarter was up 5.2% compared to the same quarter last year.

A number of other brokerages have also weighed in on AMED. Wall Street Zen lowered Amedisys from a "strong-buy" rating to a "buy" rating in a report on Saturday, May 24th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $100.00 price objective on shares of Amedisys in a report on Wednesday, April 16th.

Amedisys Stock Performance

AMED traded up $0.16 during trading on Thursday, reaching $98.67. The company's stock had a trading volume of 234,788 shares, compared to its average volume of 366,104. Amedisys has a 52-week low of $82.15 and a 52-week high of $99.00. The company's fifty day moving average price is $96.75 and its 200-day moving average price is $94.20. The company has a market capitalization of $3.25 billion, a price-to-earnings ratio of 38.39, a price-to-earnings-growth ratio of 1.33 and a beta of 0.89. The company has a debt-to-equity ratio of 0.26, a quick ratio of 1.36 and a current ratio of 1.36.

Institutional Investors Weigh In On Amedisys

Several institutional investors have recently modified their holdings of AMED. Hexagon Capital Partners LLC boosted its stake in shares of Amedisys by 108.1% during the 1st quarter. Hexagon Capital Partners LLC now owns 310 shares of the health services provider's stock worth $29,000 after acquiring an additional 161 shares in the last quarter. MassMutual Private Wealth & Trust FSB boosted its stake in shares of Amedisys by 56.1% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 334 shares of the health services provider's stock worth $31,000 after acquiring an additional 120 shares in the last quarter. Fifth Third Bancorp boosted its stake in shares of Amedisys by 68.1% during the 1st quarter. Fifth Third Bancorp now owns 348 shares of the health services provider's stock worth $32,000 after acquiring an additional 141 shares in the last quarter. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Amedisys during the 2nd quarter worth approximately $32,000. Finally, UMB Bank n.a. boosted its stake in shares of Amedisys by 100.0% during the 1st quarter. UMB Bank n.a. now owns 386 shares of the health services provider's stock worth $36,000 after acquiring an additional 193 shares in the last quarter. Hedge funds and other institutional investors own 94.36% of the company's stock.

Amedisys Company Profile

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.